Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan-Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6-10.5), and median TTP was 4.1 months (95% CI: 3.8-4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results can be used in the decision making for the early shift to second-line strategy.

Cabibbo G., Cucchetti A., Camma C., Casadei-Gardini A., Celsa C., Emanuele Maria Rizzo G., et al. (2019). Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials. FUTURE ONCOLOGY, 15(29), 3411-3422 [10.2217/fon-2019-0287].

Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials

Cabibbo G.
Primo
;
Camma C.;Celsa C.;
2019-01-01

Abstract

Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan-Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6-10.5), and median TTP was 4.1 months (95% CI: 3.8-4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results can be used in the decision making for the early shift to second-line strategy.
2019
Cabibbo G., Cucchetti A., Camma C., Casadei-Gardini A., Celsa C., Emanuele Maria Rizzo G., et al. (2019). Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials. FUTURE ONCOLOGY, 15(29), 3411-3422 [10.2217/fon-2019-0287].
File in questo prodotto:
File Dimensione Formato  
fon-2019-0287.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.74 MB
Formato Adobe PDF
1.74 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/404046
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 15
social impact